Bli medlem
Bli medlem

Du är här

2016-07-21

DSM N.V. : DSM informs market of final pricing of Patheon N.V. IPO

Royal DSM, a global science-based company active in health, nutrition and
materials, informs its stakeholders that Patheon N.V., a company in which DSM
holds approximately 53.5 million ordinary shares, has today priced
its Initial Public Offering at US$ 21.00 per ordinary share
. The pricing had been estimated at
US$ 19.00 - US$ 22.00 per ordinary share.

As part of the Initial Public Offering, DSM is offering a final total of
4,761,905 of its ordinary shares in Patheon N.V. Patheon N.V. will not
receive any proceeds from the sale of ordinary shares by DSM.

Copies of the final prospectus relating to the offering will be filed with the
U.S. Securities and Exchange Commission ("SEC") and may be obtained from:

J. P. Morgan Securities LLC
c/o Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, New York 11717
Attn: Prospectus Group
Telephone: (866) 803-9204

Morgan Stanley&Co. LLC
180 Varick Street, Second Floor
New York, New York 10014
Attn: Prospectus Department

Jefferies LLC
520 Madison Avenue, 2nd Floor
New York, New York 10022
Attn: Equity Syndicate Prospectus Department
Email: Prospectus_Department@Jefferies.com
Telephone: (877) 547-6340

UBS Securities LLC
1285 Avenue of the Americas
New York, New York 10019
Attn: Prospectus Department
Telephone: (888) 827-7275

A registration statement relating to these securities has been filed with, and
was declared effective on [20] July 2016 by, the SEC. The offering of these
securities is being made only by means of a written prospectus forming part
of the effective registration statement. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.

The statements in this press release that are not historical facts may be
forward-looking statements. Such forward looking statements, based upon
current beliefs and expectations, are subject to risks and uncertainties,
which could cause actual results to differ from the forward looking
statements. Accordingly, readers should not place undue reliance on
forward-looking statements as a prediction of actual results. For more
information concerning factors that could cause actual results to differ
materially from those conveyed in the forward-looking statements, please
refer to the "Risk Factors" section of the prospectus included in the
registration statement, in the form last filed with the SEC. DSM does not
assume any obligation to update the information contained in this press
release.

This press release may contain forward-looking statements with respect to
DSM's future (financial) performance and position. Such statements are based
on current expectations, estimates and projections of DSM and information
currently available to the company. DSM cautions readers that such statements
involve certain risks and uncertainties that are difficult to predict and
therefore it should be understood that many factors can cause actual
performance and position to differ materially from these statements. DSM has
no obligation to update the statements contained in this press release,
unless required by law. The English language version of the press release is
leading.

DSM - Bright Science. Brighter Living.(TM)

Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in life sciences and
materials sciences DSM is driving economic prosperity, environmental progress
and social advances to create sustainable value for all stakeholders
simultaneously. DSM delivers innovative solutions that nourish, protect and
improve performance in global markets such as food and dietary supplements,
personal care, feed, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials. DSM
and its associated companies deliver annual net sales of about €10 billion
with approximately 25,000 employees. The company is listed on Euronext
Amsterdam. More information can be found atwww.dsm.com.

For more information:

----------------------------------------------------------------------
| DSM Corporate Communications DSM Investor Relations |
|Herman Betten |
|tel. +31 (0) 45 5782017 Dave Huizing |
|e-mailmedia.contacts@dsm.com tel. +31 (0) 45 5782864 |
| e-mailinvestor.relations@dsm.com |
----------------------------------------------------------------------

Press release-pdf
http://hugin.info/130663/R/2029843/754901.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM N.V. via Globenewswire

HUG#2029843

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.